Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carminomycin is a toxic anthracycline antibiotic produced by the bacterium Actinomadura carminata. It acts as an antineoplastic agent with potent activity against various cancers, including metastatic breast cancer and acute myeloid leukemia. Carminomycin exerts its effects primarily by intercalating into DNA and inhibiting DNA topoisomerase II, which blocks DNA replication and repair, as well as RNA and protein synthesis, ultimately inducing apoptosis in tumor cells. The drug has also demonstrated antimicrobial properties against bacteria, viruses, and fungi. Its main toxicities include myelosuppression, gastrointestinal intolerance, alopecia (hair thinning), phlebitis, and in some cases cardiotoxicity[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carminomycin.